734 results match your criteria: "Institute for Neurodegenerative Disease[Affiliation]"

Characterization of a novel PET radioligand for mitochondrial complex I in nonhuman primate.

Nucl Med Biol

January 2025

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, United States. Electronic address:

The role of mitochondrial complex I (MC-I) dysfunction is well-documented across a range of neurodegenerative disorders. Recently, a novel positron emission tomography (PET) radioligand, [F]CNL02, has been synthesized to target MC-I. In this paper, we provide a comprehensive characterization of [F]CNL02, using nonhuman primate as a model system.

View Article and Find Full Text PDF

Prodromal Parkinson's disease and subsequent risk of Parkinson's disease and mortality.

NPJ Parkinsons Dis

January 2025

Department of Nutrition and Food Hygiene, School of Public Health, Institute of Nutrition, Zhongshan Hospital, Fudan University, Shanghai, China.

Association of prodromal Parkinson's disease (PD) with risk of PD and risk of mortality in individuals with PD warrant investigation through large-scale prospective study. We included 501,475 participants without PD at baseline. Eight prodromal features were measured.

View Article and Find Full Text PDF

Development of a PET Probe Targeting Bromodomain and Extra-Terminal Proteins for In Vitro and In Vivo Visualization.

Pharmaceuticals (Basel)

December 2024

Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.

Bromodomain and extra-terminal (BET) proteins are critical regulators of gene transcription, as they recognize acetylated lysine residues. The BD1 bromodomain of BRD4, a member of the BET family, has emerged as a promising therapeutic target for various diseases. This study aimed to develop and evaluate a novel C-11 labeled PET radiotracer, [C]YL10, for imaging the BD1 bromodomain of BRD4 in vivo.

View Article and Find Full Text PDF

Promoting Physical Activity in People With Parkinson's Disease Through a Smartphone App: A Pilot Study.

J Neurol Phys Ther

January 2025

Center of Expertise for Parkinson & Movement Disorders, Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands (S.S., N.M.V., S.K.L.D., B.R.B.); Harvard Medical School, Boston, Massachusetts (A.A., M.A.S., E.A.M.); Departments of Epidemiology and Nutrition, T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts (A.A.); Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts (M.A.S., E.A.M.); Mass General Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, Massachusetts (M.A.S.); and Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts (E.A.M.).

Background And Purpose: Physical activity has beneficial symptomatic effects for people with Parkinson's disease (PD), but increasing-and sustaining-a physically active lifestyle remains challenging. We investigated the feasibility (ability to increase step counts) and usability of a behavioral intervention using a motivational smartphone application to remotely increase physical activity in PD.

Methods: We performed a 4-week, double-blind pilot trial.

View Article and Find Full Text PDF

Stabilization of mitochondria-associated endoplasmic reticulum membranes regulates Aβ generation in a three-dimensional neural model of Alzheimer's disease.

Alzheimers Dement

December 2024

Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Henry and Allison McCance Center for Brain Health, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, USA.

Introduction: We previously demonstrated that regulating mitochondria-associated endoplasmic reticulum (ER) membranes (MAMs) affects axonal Aβ generation in a well-characterized three-dimensional (3D) neural Alzheimer's disease (AD) model. MAMs vary in thickness and length, impacting their functions. Here, we examined the effect of MAM thickness on Aβ in our 3D neural model of AD.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated how combinations of specific signs and symptoms can identify individuals in the early stages of Parkinson's disease (PD), analyzing data from over 6,100 men for an average of 3.4 years.
  • Findings revealed that men with constipation, probable REM sleep behavior disorder (pRBD), and hyposmia had a significantly higher risk (23-fold) of developing PD compared to those without these symptoms, and similar high risks were associated with a calculated probability of prodromal PD.
  • The research suggests that these symptom combinations can be effective in predicting future PD and could be used in screening efforts for potential prevention trials.
View Article and Find Full Text PDF

Integrative pathway analysis across humans and 3D cellular models identifies the p38 MAPK-MK2 axis as a therapeutic target for Alzheimer's disease.

Neuron

January 2025

Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA; McCance Center for Brain Health, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address:

Article Synopsis
  • Alzheimer's disease (AD) poses significant treatment challenges, particularly targeting amyloid-β (Aβ), but a new analysis method uncovered 83 dysfunctional pathways relevant to AD in both human brains and lab models.
  • The p38 MAPK pathway was notably upregulated and linked to tau pathology and neuronal damage, highlighting its potential as a therapeutic target.
  • By using integrative pathway activity analysis (IPAA), researchers can combine human data with cellular models to efficiently identify promising drug targets for AD treatment.*
View Article and Find Full Text PDF

Differential regulation of brain microvessel transcriptome and brain metabolome by western and heart-healthy dietary patterns in Ossabaw pigs.

Sci Rep

November 2024

Cardiovascular Nutrition Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, 711 Washington Street, Boston, MA, 02111, USA.

Diet is a potentially modifiable neurodegenerative disease risk factor. We studied the effects of a typical Western diet (WD; high in refined carbohydrates, cholesterol and saturated fat), relative to a heart-healthy diet (HHD; high in unrefined carbohydrates, polyunsaturated fat and fiber, and low in cholesterol) on brain microvessel transcriptomics and brain metabolomics of the temporal region in Ossabaw minipigs. Thirty-two pigs (16 male and 16 females) were fed a WD or HHD starting at the age of 4 months for a period of 6 months.

View Article and Find Full Text PDF

Oligonucleotide therapeutics (ASOs and siRNAs) have been explored for modulation of gene expression in the central nervous system (CNS), with several drugs approved and many in clinical evaluation. Administration of highly concentrated oligonucleotides to the CNS can induce acute neurotoxicity. We demonstrate that delivery of concentrated oligonucleotides to the CSF in awake mice induces acute toxicity, observable within seconds of injection.

View Article and Find Full Text PDF

Targeted Degradation of Receptor-Interacting Protein Kinase 1 to Modulate the Necroptosis Pathway.

ACS Pharmacol Transl Sci

November 2024

Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, United States.

Necroptosis is a highly regulated form of necrotic cell death that plays an essential role in pathogen defense and tissue homeostasis. Abnormal regulation of the necroptotic pathway has been implicated in the pathogenesis of various human diseases, including cancer, inflammatory, and neurodegenerative diseases. Receptor-interacting protein kinase 1 (RIPK1) serves as a crucial regulator of the necroptotic signaling pathway and has been identified as a potential therapeutic target.

View Article and Find Full Text PDF

Approaches for studying neuroimmune interactions in Alzheimer's disease.

Trends Immunol

December 2024

Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. Electronic address:

Peripheral immune cells play an important role in the pathology of Alzheimer's disease (AD), impacting processes such as amyloid and tau protein aggregation, glial activation, neuronal integrity, and cognitive decline. Here, we examine cutting-edge strategies - encompassing animal and cellular models - used to investigate the roles of peripheral immune cells in AD. Approaches such as antibody-mediated depletion, genetic ablation, and bone marrow chimeras in mouse models have been instrumental in uncovering T, B, and innate immune cell disease-modifying functions.

View Article and Find Full Text PDF

Background: White matter hyperintensities (WMHs) are frequently observed on magnetic resonance imaging (MRI) in patients with cerebral amyloid angiopathy (CAA). The neuropathological substrates that underlie WMHs in CAA are unclear, and it remains largely unexplored whether the different WMH distribution patterns associated with CAA (posterior confluent and subcortical multispot) reflect alternative pathophysiological mechanisms.

Methods And Results: We performed a combined in vivo MRI-ex vivo MRI-neuropathological study in patients with definite CAA.

View Article and Find Full Text PDF

The brain pathobiome in Alzheimer's disease.

Neurotherapeutics

October 2024

Genetics and Aging Research Unit, Henry and Allison McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA, 02129, USA; Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA. Electronic address:

View Article and Find Full Text PDF

Aims: Although the genetic locus of X-linked dystonia parkinsonism (XDP), a neurodegenerative disease endemic in the Philippines, is well-characterized, the exact mechanisms leading to neuronal loss are not yet fully understood. Recently, we demonstrated an increase in myeloperoxidase (MPO) levels in XDP postmortem prefrontal cortex (PFC), suggesting a role for inflammation in XDP pathogenesis. Therefore, we hypothesized that inhibiting MPO could provide a therapeutic strategy for XDP.

View Article and Find Full Text PDF

The Effect of Pexidartinib on Neuropathic Pain via Influences on Microglia and Neuroinflammation in Mice.

Anesth Analg

October 2024

Genetics and Aging Research Unit, Department of Neurology, McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Background: Chronic pain is a debilitating medical condition that lacks effective treatments. Increasing evidence suggests that microglia and neuroinflammation underlie pain pathophysiology, which therefore supports a potential strategy for developing pain therapeutics. Here, our study is testing the hypothesis that the promise of pain amelioration can be achieved using the small-molecule pexidartinib (PLX-3397), a previously food and drug administration (FDA)-approved cancer medicine and a colony-stimulating factor-1 receptor (CSF-1R) inhibitor that display microglia-depleting properties.

View Article and Find Full Text PDF
Article Synopsis
  • Duplications of a specific region on the X chromosome known as Xq28,distal have been linked to schizophrenia (SCZ) and intellectual disability in both males and females, though the exact genes involved remain unclear.
  • This study aimed to explore rare genetic variants in the Xq28,distal locus and how they might contribute to SCZ risk, using advanced sequencing methods on a large sample of patients and controls.
  • Despite identifying some potentially functional variants, the analysis did not find a significant difference between patients with SCZ and controls, suggesting that more research is needed to understand the role of X-chromosomal factors in neuropsychiatric disorders.
View Article and Find Full Text PDF

PS1/gamma-secretase acts as rogue chaperone of glutamate transporter EAAT2/GLT-1 in Alzheimer's disease.

Acta Neuropathol Commun

October 2024

Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA.

The recently discovered interaction between presenilin 1 (PS1), a subunit of γ-secretase involved in amyloid-β (Aβ) peptide production, and GLT-1, the major brain glutamate transporter (EAAT2 in the human), may link two pathological aspects of Alzheimer's disease: abnormal Aβ occurrence and neuronal network hyperactivity. In the current study, we employed a FRET-based fluorescence lifetime imaging microscopy (FLIM) to characterize the PS1/GLT-1 interaction in brain tissue from sporadic AD (sAD) patients. sAD brains showed significantly less PS1/GLT-1 interaction than those with frontotemporal lobar degeneration or non-demented controls.

View Article and Find Full Text PDF

Glutamate Transporter 1 as a Novel Negative Regulator of Amyloid β.

Cells

September 2024

Alzheimer Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, 114, 16th Street, Charlestown, MA 02129, USA.

Article Synopsis
  • * The study identifies a direct interaction between GLT-1 and Presenilin 1 (PS1), revealing that GLT-1 can lower amyloid-beta (Aβ) production by altering γ-secretase activity, thereby affecting how amyloid precursor protein (APP) is processed.
  • * Targeting the GLT-1/PS1 interaction may serve as a promising new therapeutic approach to manage AD, as inhibiting this interaction increases Aβ levels, suggesting its critical role in disease progression.*
View Article and Find Full Text PDF

Microglia are critical innate immune cells of the brain. targeting of microglia using gene-delivery systems is crucial for studying brain physiology and developing gene therapies for neurodegenerative diseases and other brain disorders such as NeuroAIDS. Historically, microglia have been extremely resistant to transduction by viral vectors, including adeno-associated virus (AAV) vectors.

View Article and Find Full Text PDF

Recording γ-secretase activity in living mouse brains.

Elife

October 2024

MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, United States.

γ-Secretase plays a pivotal role in the central nervous system. Our recent development of genetically encoded Förster resonance energy transfer (FRET)-based biosensors has enabled the spatiotemporal recording of γ-secretase activity on a cell-by-cell basis in live neurons . Nevertheless, how γ-secretase activity is regulated remains unclear.

View Article and Find Full Text PDF
Article Synopsis
  • * Recent studies link the disruption of palmitoylation to neurodegenerative diseases, impacting proteins like amyloid precursor protein, BACE1, and others involved in neuronal dysfunction.
  • * The review discusses new findings on palmitoylation's role in neurodegeneration and investigates potential treatments that could target this process.
View Article and Find Full Text PDF

Engineered 3D human neurovascular model of Alzheimer's disease to study vascular dysfunction.

Biomaterials

March 2025

Department of Mechanical Engineering and Biological Engineering, Massachusetts Institute of Technology, Cambridge MA, 02139, USA. Electronic address:

The blood-brain barrier (BBB) serves as a selective filter that prevents harmful substances from entering the healthy brain. Dysfunction of this barrier is implicated in several neurological diseases. In the context of Alzheimer's disease (AD), BBB breakdown plays a significant role in both the initiation and progression of the disease.

View Article and Find Full Text PDF

The tauopathies are defined by pathological tau protein aggregates within a spectrum of clinically heterogeneous neurodegenerative diseases. The primary tauopathies meet the definition of rare diseases in the United States. There is no approved treatment for primary tauopathies.

View Article and Find Full Text PDF